We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

115 hedge funds and large institutions have $179M invested in Palvella Therapeutics in 2018 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 45 increasing their positions, 30 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

50% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 30

0.02% more ownership

Funds ownership: 0.79% → 0.82% (+0.02%)

0% more funds holding

Funds holding: 115 → 115 (0)

0% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 20

23% less capital invested

Capital invested by funds: $232M → $179M (-$53.7M)

100% less call options, than puts

Call options by funds: $1K | Put options by funds: $486K

Holders
115
Holders Change
–
Holders Change %
0%
% of All Funds
2.63%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
20
Increased
45
Reduced
30
Closed
20
Calls
$1K
Puts
$486K
Net Calls
-$485K
Net Calls Change
+$244K

Top Buyers

1
BI
BVF Inc
California
+$10.4M
2
BlackRock
BlackRock
New York
+$5.26M
3
PM
Prosight Management
Texas
+$4.74M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$3.95M
5
American Century Companies
American Century Companies
Missouri
+$2.57M

Top Sellers

1
O
OrbiMed
New York
-$14.3M
2
Morgan Stanley
Morgan Stanley
New York
-$5.2M
3
Millennium Management
Millennium Management
New York
-$4.42M
4
EI
EAM Investors
California
-$3.56M
5
AL
AJO LP
Pennsylvania
-$2.96M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
76
Bank of America
North Carolina
$119K +$12.4K +26 +10%
Marshall Wace
77
Marshall Wace
United Kingdom
$118K +$139K +292 New
TI
78
Trexquant Investment
Connecticut
$113K -$411K -864 -76%
VOYA Investment Management
79
VOYA Investment Management
Georgia
$112K +$14.8K +31 +13%
PPA
80
Parametric Portfolio Associates
Washington
$111K -$697K -1,465 -84%
Ohio Public Employees Retirement System (OPERS)
81
Ohio Public Employees Retirement System (OPERS)
Ohio
$110K +$129K +271 New
CAN
82
Cetera Advisor Networks
California
$109K – – –
MIM
83
MetLife Investment Management
New Jersey
$105K – – –
Man Group
84
Man Group
United Kingdom
$90K +$2.85K +6 +3%
Balyasny Asset Management
85
Balyasny Asset Management
Illinois
$85K +$99.9K +210 New
Commonwealth Equity Services
86
Commonwealth Equity Services
Massachusetts
$82K +$95.6K +201 New
MLICM
87
Metropolitan Life Insurance Company (MetLife)
New York
$79.4K +$8.57K +18 +10%
WJA
88
Williams Jones & Associates
New York
$71K – – –
CS
89
Credit Suisse
Switzerland
$69K -$11.4K -24 -12%
FLPIM
90
F.L. Putnam Investment Management
Massachusetts
$67K – – –
Parallax Volatility Advisers
91
Parallax Volatility Advisers
California
$59K – – –
JP Morgan Chase
92
JP Morgan Chase
New York
$53K -$1.02M -2,150 -94%
State Board of Administration of Florida Retirement System
93
State Board of Administration of Florida Retirement System
Florida
$52K – – –
US Bancorp
94
US Bancorp
Minnesota
$52K – – –
JT
95
Jump Trading
Illinois
$51K +$60K +126 New
MAM
96
Meeder Asset Management
Ohio
$46.9K +$45.2K +95 +452%
Legal & General Group
97
Legal & General Group
United Kingdom
$39K +$7.14K +15 +18%
Citigroup
98
Citigroup
New York
$38K +$18.1K +38 +69%
UBS Group
99
UBS Group
Switzerland
$33K +$38.5K +81 New
Russell Investments Group
100
Russell Investments Group
United Kingdom
$31K -$11.4K -24 -24%
2 3
4
5 6

PVLA Hedge Fund Activity: Q2 2018 in Review

115 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2018, worth a combined $179M — down 23% from $232M a quarter earlier.

Fund positioning in PVLA was balanced in Q2 2018: 20 funds opened new positions, 20 closed out, 45 added to existing stakes and 30 trimmed.

The largest buyer was BVF Inc, adding an estimated $10.4M. The largest seller was OrbiMed, cutting an estimated $14.3M.

  • 115 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2018, unchanged from Q1 2018.
  • Funds reported $179M of Palvella Therapeutics stock for Q2 2018, down 23% quarter-over-quarter.
  • 20 funds opened new Palvella Therapeutics positions in Q2 2018 and 20 closed out, a net change of 0 holders.
  • The largest Palvella Therapeutics buyer in Q2 2018 was BVF Inc, an estimated $10.4M added.
  • The largest Palvella Therapeutics seller in Q2 2018 was OrbiMed, an estimated $14.3M sold.

Based on aggregated 13F filings for Q2 2018.